AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04891939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education lessons (Smart-Kid's program)
Description: The intervention is designed for all students, including never-smokers and students at high risk for smoking. Therefore, some contents are intended to influence those high-risk youth within the larger student audience by targeting the stages of the smoking acquisition process including, preparation, initiation, experimentation, regular use, and addiction (Mayhew et al., 2000). The intervention is also focused on addressing risk factors for smoking initiation and continue use (Hansen et al., 2015; So \& Yeo, 2015). These risk factors are, therefore, grouped into four major groups namely; personal factors, behavioral factors, environmental factors and sociodemographic factors
Study NCT04891939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: School Health and Education Program (SHEP)
Description: The SHEP is the usual health and education program been done in all schools, and also has tobacco control component. This is will be used as the control for the intervention.
Study NCT05345210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
Study NCT05345210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Fumarate+Amoxycillin 14days (VA14)
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
Study NCT05345210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Fumarate+Amoxycillin 7days (VA7)
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
Study NCT05345210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
Study NCT05345210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days
Study NCT06024876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS-101
Description: Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
Study NCT04919967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual implementation protocol
Description: Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course and also receive additional assistance through Virtual Implementation support. The Virtual Implementation strategy will be provided through virtual assistance, training, and toolkits to help obstetric practices integrate perinatal mental health and obstetric care and is delivered over 2-3 months and includes two 1-hour virtual implementation e-meetings. Implementation will occur within the practice where a champion is identified who establishes a quality improvement team to implement the practice's change plan to achieve their goals of addressing perinatal mental health conditions.
Study NCT04919967 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-learning toolkit
Description: A toolkit given to obstetric care providers to enhance knowledge about and screening for perinatal mood and anxiety disorders. Participants assigned to the e-learning/toolkit alone group will take an e-learning course.This four-part online learning course aims to help obstetric care practitioners address perinatal mental health conditions such as depression, anxiety, PTSD and bipolar disorder.
Study NCT04919967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-learning toolkit
Description: A toolkit given to obstetric care providers to enhance knowledge about and screening for perinatal mood and anxiety disorders. Participants assigned to the e-learning/toolkit alone group will take an e-learning course.This four-part online learning course aims to help obstetric care practitioners address perinatal mental health conditions such as depression, anxiety, PTSD and bipolar disorder.
Study NCT06182267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L Arginine
Description: toothpaste
Study NCT06182267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L Arginine
Description: toothpaste
Study NCT06182267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride
Description: toothpaste
Study NCT06182267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride
Description: toothpaste
Study NCT05956418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centhaquine
Description: Centhaquine (LYFAQUIN™ or centhaquine citrate) is a novel, first-in-class, highly effective resuscitative agent for hypovolemic shock. Phase II results demonstrate highly significant efficacy in improving blood pressure (p\<0.0001), lactate levels (p=0.0012) and base-deficit (p\<0.0001). There was also improvement in reduction in use of vasopressors and reduced mortality. Similarly, results of phase III study confirmed the safety and efficacy of centhaquine as an adjuvant to standard of care for hypovolemic shock. Therefore, to assess safety of centhaquine in large population a phase IV study (post-authorization safety study) has been designed.
Study NCT05955560 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PureWick Male External Catheter
Description: The PureWick™ Male External Catheter (MEC) is intended for non-invasive urine output management in male patients. It is a single-use, non-sterile device. The PureWick™ Male External Catheter is a commercially available device which is Class I, 510(K) exempt.
Study NCT05955560 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sage PrimoFit
Description: The PrimoFit External Urine Management for the Male Anatomy is indicated for the non-invasive external collection of urine for adult patients with male anatomy who require urine management. It is a single-use, non-sterile device. The Sage PrimoFit is a commercially available device which is Class I, 510(K) exempt.
Study NCT03997318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMDC-USR
Description: Autologous Muscle Derived Cells for Urinary Sphincter Repair
Study NCT03997318 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control is the vehicle solution used for the study product.
Study NCT06399146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus App
Description: Take a photo off the patient's skin (sternum).
Study NCT00013130 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provision of health status information to patients provider
Study NCT05516251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Supraorbital Nerve Stimulator
Description: SNS devices (DJTT-Ib, Hengyang Dajing Medical Instrument Technology Co., Ltd.) Stimulation electrodes are placed on the bilateral forehead, covering the supratrochlear and supraorbital nerves. The stimulus parameters are set as follows: pulse width 300 μsec, frequency 60 Hz, pulse duration μsec, increasing current peaked at 14 min with 16 mA. Patients receive SNS treatment daily for 20 min, no lease than 5 per week, last for 4 weeks.
Study NCT05516251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate 25Mg Tab
Description: Topiramate 25Mg Tab (Tuotai Pian, Xian Janssen Pharmaceutical Ltd.) are prescribed to participates by one neurologist. Participates are asked to take 25mg oral per day in a fixed time usually in the morning.
Study NCT06107491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative educational videos plus routine education
Description: Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
Study NCT06107491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative routine education
Description: Mothers receiving routine education before their children receiving congenital heart disease surgery
Study NCT04963179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Womed Leaf
Description: Womed Leaf™ device is composed of a uterine anti-adhesion film pre-loaded inside a flexible inserter.~Womed Leaf™ is inserted in the uterine cavity by the gynecologist surgeon as a film folded into a 5 mm diameter flexible inserter. Once released, the film will unfold and swell into the uterine cavity to keep uterus walls separated during approximately 5 days. It is degraded and discharged naturally through the cervix and vagina in less than 30 days.
Study NCT03522155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered communication of life expectancy
Description: The intervention arm will test if patient-specific LE estimates via a targeted, patient-centered communication approach paired with LE-specific conjoint analysis data improves decisional conflict, quality of LE discussion, and reduces rates of overtreatment of Genitourinary malignancies.
Study NCT04931225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Landiolol
Description: Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
Study NCT06293846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: What I Learned at Home
Description: What I Learned at Home is a self-efficacy intervention intended to build home repair and management skills while improving performance self-efficacy.
Study NCT05724602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant
Description: 3 cycles of xevinapant + IMRT followed by 3 cycles of xevinapant as monotherapy
Study NCT05724602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 cycles of placebo + IMRT followed by 3 cycles of placebo as monotherapy
Study NCT06174441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Investigational product 1 (CPMSM)
Description: Test group 1 will receive investigational product 1 (CPMSM: daily dose 25 mL contains: Hydrolyzed fish collagen 5 g, methylsulphonylmethane (MSM) 1,5 g, Biotin 150 μg, Vitamin B6 1,6 mg, Zinc 2 mg, Vitamin C 120 mg).
Study NCT06174441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Investigational product 2 (HC+)
Description: Test group 2 (TG2) will receive investigational product 2 (HC+: daily dose 25 mL contains: Niacin 16 mg, Pantothenic acid 6 mg, Biotin 500 μg, Vitamin B6 1,4 mg, Folic acid 200 μg, Zinc 2 mg, Pea sprout extract 100 mg, Horsetail aerial parts extract 70 mg, Ashwagandha root extract 40 mg, Saw palmetto fruit extract 40 mg, Nettle leaves extract 30 mg, Grape seed extract 10 mg).
Study NCT06174441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group (PG) will receive placebo product without any of the active ingredients (PL, daily dose 25 mL: no active ingredients).
Study NCT05024565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prolonged intravenous infusion of β-lactams Antibiotics
Description: (1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
Study NCT05061160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Aerobic Exercise training Group
Description: Interval Aerobic exercise will be on upper limb Bicycle with a pause of 3 mins interval Interval Aerobic Exercises: Frequency= 3 times per week Intensity= 50% of heart rate reserve for 2 mins 80% of heart rate reserve for 1 min Type= interval aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down.
Study NCT05061160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Aerobic Exercise training Group
Description: Continuous Aerobic exercise will be on upper limb Bicycle Continuous Aerobic Exercise: Frequency= 3 times per week Intensity= 50% of heart rate reserve Type= continuous aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down.
Study NCT05996081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence toolkit
Description: The adherence toolkit consists of a flowchart of adherence intervention, a self-reported adherence questionnaire, and an intervention wheel as a decision support tool for a healthcare provider. The toolkit can guide HIV care providers to identify problems causing nonadherence and to tailor the effective interventions based on the individual problems. It is available in a Bahasa Indonesia version, accompanied by a user guide on the practical application of the intervention, and can be used digitally or printed on paper. The intervention wheel is an integrated HIV medication adherence influencing factors and effective adherence-promoting interventions derived from systematic reviews and meta analyses, including previous studies conducted in Indonesia.
Study NCT04831502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 Tablets.
Study NCT04831502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 Capsules.
Study NCT04429009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZEPHYRx Respiratory Therapy (RT) System
Description: A breath controlled video game system for respiratory therapy
Study NCT04429009 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Incentive Spirometer
Description: A simple (not digital) plastic device that contains a piston that rises inside the device and measures the volume of your breath
Study NCT05702320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the heating procedure
Description: The patients will undergo a heating procedure.
Study NCT05900427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
Study NCT05900427 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
Study NCT06218004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab combined with chemotherapy
Description: envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
Study NCT04991480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART4215
Description: Participants will receive ART4215 by mouth daily in 21-day cycles.
Study NCT04991480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.
Study NCT04991480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered at a dose of 200 mg or 300 mg by mouth daily in 21-day cycles.
Study NCT06316466 — intervention group
Intervention type: OTHER
Intervention: Lp(a)
Description: The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.
Study NCT06055426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bed bath application
Description: Patients who agree to participate in the research and are assigned to the experimental group will receive a bed bath. In order to examine the short-term, medium-term and long-term effects of bed bath, it is planned to have the whole body bed bath performed by the researcher nurse xx three times a week, two days apart.
Study NCT04879745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyVoice:Rheum
Description: Participants will be given access to MyVoice:Rheum, a web-based decision aid (DA).
Study NCT04879745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet
Description: Participants in this arm will be given a copy of an existing patient pamphlet
Study NCT05740722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamid riboside
Description: 500 mg x 2 po
Study NCT05740722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets
Study NCT05925894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma
Description: 60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.
Study NCT05925894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma
Description: 60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.
Study NCT06018961 — intervention group
Intervention type: OTHER
Intervention: Post-operative ileus surgery
Description: Collection of ileus events, items of IFEED score and surgical complications
Study NCT06116253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) Scan
Description: Participants will undergo a 1-hour research MRI scan.
Study NCT06116253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc-99m Pentetate
Description: Participants will receive radioisotope (99mTc-DTPA) injection (5 mCi) during 3-5 hour scanning session to estimate measured glomerular filtration rate (mGFR).
Study NCT05920941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]JAB-21822
Description: Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach
Study NCT05471362 — intervention group
Intervention type: DEVICE
Intervention: Postpartum IUD
Description: Postpartum IUD prevents pregnancy and short inter-pregnancy interval and allow spacing and family regulation
Study NCT05062668 — intervention group
Intervention type: PROCEDURE
Intervention: cataract operation and istent
Description: a cataract operation and the placement of one or two iStent inject or inject W at the same time
Study NCT05062668 — intervention group
Intervention type: PROCEDURE
Intervention: cataract operation only
Description: Patients have a classic postoperative treatment after cataract.
Study NCT05147857 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilapan s
Description: is an osmotic hygroscopic dilator produced from a patented Aquacryl® hydrogel that guarantees consistency of action.~It is a rigid gel rod that increases in volume by absorbing fluids from the cervical canal, so it gradually dilates the cervix The thin 4 mm rod can expand up to 15 mm over a 12-24 hours period. This allows it to dilate and soften the cervix gradually.